Cytosorbents Crp (CTSO)

Currency in USD
0.916
-0.017(-1.82%)
Closed·
0.900-0.016(-1.71%)
·
CTSO Scorecard
Full Analysis
Quickly burning through cash
CTSO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9000.950
52 wk Range
0.7101.610
Key Statistics
Prev. Close
0.932
Open
0.928
Day's Range
0.9-0.95
52 wk Range
0.71-1.61
Volume
126.02K
Average Volume (3m)
166.64K
1-Year Change
-12.76%
Book Value / Share
0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTSO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.000
Upside
+445.85%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Cytosorbents Crp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Cytosorbents Crp Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Cytosorbents Crp Earnings Call Summary for Q2/2025

  • Q2 2025 revenue of $9.6M, up 9% YoY but below $10.25M forecast; EPS loss of $0.05 vs expected $0.04 loss
  • Stock dipped 1% in aftermarket trading; company maintains strong liquidity with current ratio of 2.61
  • Focus on regulatory approvals for DrugSorb ATR device; decisions from FDA and Health Canada expected in 2025
  • Revenue projections: $10.36M for Q3 2025, $10.8M for Q4 2025; aim for near-breakeven by end of 2025
  • Challenges include pending regulatory approvals, market competition, economic pressures, and cash burn management
Last Updated: 08/08/2025, 10:50
Read Full Transcript

Compare CTSO to Peers and Sector

Metrics to compare
CTSO
Peers
Sector
Relationship
P/E Ratio
−5.8x−5.5x−0.7x
PEG Ratio
−0.09−0.190.00
Price/Book
5.0x9.8x2.6x
Price / LTM Sales
1.6x4.1x3.4x
Upside (Analyst Target)
336.7%34.7%38.0%
Fair Value Upside
Unlock−6.6%5.3%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.000
(+445.85% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.05 / -0.04
Revenue / Forecast
9.60M / 10.25M
EPS Revisions
Last 90 days

CTSO Income Statement

People Also Watch

3.740
NUVB
-0.27%
1.900
DVLT
-16.67%
0.379
CODX
-11.86%
1.810
HYFT
-8.12%
0.885
COCH
-6.74%

FAQ

What Stock Exchange Does Cytosorbents Crp Trade On?

Cytosorbents Crp is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cytosorbents Crp?

The stock symbol for Cytosorbents Crp is "CTSO."

What Is the Cytosorbents Crp Market Cap?

As of today, Cytosorbents Crp market cap is 57.48M.

What Is Cytosorbents Crp's Earnings Per Share (TTM)?

The Cytosorbents Crp EPS (TTM) is -0.17.

When Is the Next Cytosorbents Crp Earnings Date?

Cytosorbents Crp will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is CTSO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cytosorbents Crp Stock Split?

Cytosorbents Crp has split 1 times.

How Many Employees Does Cytosorbents Crp Have?

Cytosorbents Crp has 149 employees.

What is the current trading status of Cytosorbents Crp (CTSO)?

As of 11 Oct 2025, Cytosorbents Crp (CTSO) is trading at a price of 0.916, with a previous close of 0.93. The stock has fluctuated within a day range of 0.900 to 0.950, while its 52-week range spans from 0.710 to 1.610.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.